Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs... Show more
VTRS's Aroon Indicator triggered a bullish signal on September 03, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 200 similar instances where the Aroon Indicator showed a similar pattern. In of the 200 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
VTRS moved above its 50-day moving average on August 07, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VTRS advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
VTRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for VTRS moved out of overbought territory on August 26, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 03, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VTRS as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VTRS turned negative on August 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.761) is normal, around the industry mean (16.645). P/E Ratio (236.200) is within average values for comparable stocks, (74.808). Projected Growth (PEG Ratio) (0.145) is also within normal values, averaging (1.891). Dividend Yield (0.047) settles around the average of (0.030) among similar stocks. P/S Ratio (0.856) is also within normal values, averaging (49.079).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VTRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VTRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Industry PharmaceuticalsGeneric
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
EMGF | 55.88 | 0.60 | +1.09% |
iShares Em Mkts Eq Fac ETF | |||
LCTD | 53.31 | 0.53 | +1.00% |
BlackRock World ex US Cbn Tnstn Rdns ETF | |||
EHLS | 22.63 | 0.04 | +0.18% |
Even Herd Long Short ETF | |||
GMNY | 49.69 | 0.09 | +0.18% |
Goldman Sachs Dynamic New Yor Mun IncETF | |||
MNTL | 23.80 | N/A | N/A |
Tema ETF Trust Tema Neuroscience and Mental Health ETF |
A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.
Ticker / NAME | Correlation To VTRS | 1D Price Change % | ||
---|---|---|---|---|
VTRS | 100% | -0.68% | ||
ELAN - VTRS | 53% Loosely correlated | +2.45% | ||
ZTS - VTRS | 46% Loosely correlated | +0.80% | ||
AMRX - VTRS | 44% Loosely correlated | +2.75% | ||
EBS - VTRS | 40% Loosely correlated | +3.26% | ||
COLL - VTRS | 37% Loosely correlated | +3.58% | ||
More |
Ticker / NAME | Correlation To VTRS | 1D Price Change % |
---|---|---|
VTRS | 100% | -0.68% |
Pharmaceuticals: Generic industry (221 stocks) | 15% Poorly correlated | +0.66% |